Somatostatin Receptor Positive Sstr clinical trials

Explore recruiting somatostatin receptor positive sstr clinical trials.

Recruiting somatostatin receptor positive sstr studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Somatostatin Receptor Positive Sstr trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET)

Italy, Spain, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Poland, Austria, Netherlands, Spain, France, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor‑positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin

Netherlands, Spain, Italy, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Somatostatin Receptor Positive Sstr trials by city

Somatostatin Receptor Positive Sstr in Toronto Somatostatin Receptor Positive Sstr in Vancouver Somatostatin Receptor Positive Sstr in Montreal Somatostatin Receptor Positive Sstr in Calgary Somatostatin Receptor Positive Sstr in Edmonton Somatostatin Receptor Positive Sstr in Ottawa Somatostatin Receptor Positive Sstr in Winnipeg Somatostatin Receptor Positive Sstr in Quebec City Somatostatin Receptor Positive Sstr in Hamilton Somatostatin Receptor Positive Sstr in Kitchener Somatostatin Receptor Positive Sstr in London Somatostatin Receptor Positive Sstr in Halifax Somatostatin Receptor Positive Sstr in New York Somatostatin Receptor Positive Sstr in Los Angeles Somatostatin Receptor Positive Sstr in Chicago Somatostatin Receptor Positive Sstr in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease